New Delhi: Russia is looking for a partnership with India for mass production of the COVID-19 vaccine, Sputnik V, developed in that country.
This was announced by Kirill Dmitriev, the CEO of the Russian Direct Investment Fund (RDIF) on Thursday.
Earlier, Russian President Vladimir Putin had announced that his country has developed the world’s first vaccine against COVID-19, which works “quite effectively” and forms a “stable immunity” against the disease. Sputnik V was developed by Gamaleya Research Institute along with RDIF. The vaccine, however, has not been tested in Phase 3 or larger clinical trials.
Addressing an online press briefing, Dmitriev said several nations are interested in the production of the vaccine from countries in Latin America, Asia and the Middle East, Zee News reported.
“The production of the vaccine is a very important issue. Currently, we are looking for a partnership with India. We believe that they are capable of producing the Gamaleya vaccine and it is very important to say that those partnerships to produce the vaccine will enable us to cover the demand that we have,” he said.
“We are going to do clinical trials not just in Russia but also in the UAE, Saudi Arabia, probably in Brazil and India,” he added.
Also Read: Phase III Trials Of Oxford COVID-19 Vaccine Likely To begin In India On Saturday
Also Read: COVID Vaccine To Be Commercially Available By December-End, Claims Chinese Company
